The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, B.
Right arrow Articles by Yan, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, B.
Right arrow Articles by Yan, J.
The Journal of Immunology, 2006, 177: 1661-1669.
Copyright © 2006 by The American Association of Immunologists

Yeast beta-Glucan Amplifies Phagocyte Killing of iC3b-Opsonized Tumor Cells via Complement Receptor 3-Syk-Phosphatidylinositol 3-Kinase Pathway1

Bing Li2, Daniel J. Allendorf2, Richard Hansen, Jose Marroquin, Chuanlin Ding, Daniel E. Cramer and Jun Yan3

Tumor Immunobiology Program, James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202

Anti-tumor mAbs hold promise for cancer therapy, but are relatively inefficient. Therefore, there is a need for agents that might amplify the effectiveness of these mAbs. One such agent is beta-glucan, a polysaccharide produced by fungi, yeast, and grains, but not mammalian cells. beta-Glucans are bound by C receptor 3 (CR3) and, in concert with target-associated complement fragment iC3b, elicit phagocytosis and killing of yeast. beta-Glucans may also promote killing of iC3b-opsonized tumor cells engendered by administration of anti-tumor mAbs. In this study, we report that tumor-bearing mice treated with a combination of beta-glucan and an anti-tumor mAb show almost complete cessation of tumor growth. This activity evidently derives from a 25-kDa fragment of beta-glucan released by macrophage processing of the parent polysaccharide. This fragment, but not parent beta-glucan, binds to neutrophil CR3, induces CBRM 1/5 neoepitope expression, and elicits CR3-dependent cytotoxicity. These events require phosphorylation of the tyrosine kinase, Syk, and consequent PI3K activation because beta-glucan-mediated CR3-dependent cytotoxicity is greatly decreased by inhibition of these signaling molecules. Thus, beta-glucan enhances tumor killing through a cascade of events, including in vivo macrophage cleavage of the polysaccharide, dual CR3 ligation, and CR3-Syk-PI3K signaling. These results are important inasmuch as beta-glucan, an agent without evident toxicity, may be used to amplify tumor cell killing and may open new opportunities in the immunotherapy of cancer.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
N. N. Gorgani, J. Q. He, K. J. Katschke Jr., K. Y. Helmy, H. Xi, M. Steffek, P. E. Hass, and M. van Lookeren Campagne
Complement Receptor of the Ig Superfamily Enhances Complement-Mediated Phagocytosis in a Subpopulation of Tissue Resident Macrophages
J. Immunol., December 1, 2008; 181(11): 7902 - 7908.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
T. E. Morrison, J. D. Simmons, and M. T. Heise
Complement Receptor 3 Promotes Severe Ross River Virus-Induced Disease
J. Virol., November 15, 2008; 82(22): 11263 - 11272.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Salvador, B. Li, R. Hansen, D. E. Cramer, M. Kong, and J. Yan
Yeast-Derived {beta}-Glucan Augments the Therapeutic Efficacy Mediated by Anti-Vascular Endothelial Growth Factor Monoclonal Antibody in Human Carcinoma Xenograft Models
Clin. Cancer Res., February 15, 2008; 14(4): 1239 - 1247.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. A. Horan, K.-i. Watanabe, A. M. Kong, C. G. Bailey, J. E. J. Rasko, T. Sasaki, and C. A. Mitchell
Regulation of Fc{gamma}R-stimulated phagocytosis by the 72-kDa inositol polyphosphate 5-phosphatase: SHIP1, but not the 72-kDa 5-phosphatase, regulates complement receptor 3 mediated phagocytosis by differential recruitment of these 5-phosphatases to the phagocytic cup
Blood, December 15, 2007; 110(13): 4480 - 4491.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Busetto, E. Trevisan, E. Decleva, P. Dri, and R. Menegazzi
Chloride Movements in Human Neutrophils during Phagocytosis: Characterization and Relationship to Granule Release
J. Immunol., September 15, 2007; 179(6): 4110 - 4124.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Li, M. E. Williams, J. B. Cousar, A. W. Pawluczkowycz, M. A. Lindorfer, and R. P. Taylor
Rituximab-CD20 Complexes Are Shaved from Z138 Mantle Cell Lymphoma Cells in Intravenous and Subcutaneous SCID Mouse Models
J. Immunol., September 15, 2007; 179(6): 4263 - 4271.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Li, D. J. Allendorf, R. Hansen, J. Marroquin, D. E. Cramer, C. L. Harris, and J. Yan
Combined Yeast {beta}-Glucan and Antitumor Monoclonal Antibody Therapy Requires C5a-Mediated Neutrophil Chemotaxis via Regulation of Decay-Accelerating Factor CD55
Cancer Res., August 1, 2007; 67(15): 7421 - 7430.
[Abstract] [Full Text] [PDF]

Home page
 Innate ImmunityHome page
R. Kikkert, I. Bulder, E. R. de Groot, L. A. Aarden, and M. A. Finkelman
Potentiation of Toll-like receptor-induced cytokine production by (1->3)-{beta}-D-glucans: implications for the monocyte activation test
Innate Immunity, June 1, 2007; 13(3): 140 - 149.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.